Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 22,400 shares, a decline of 74.2% from the February 28th total of 86,700 shares. Based on an average trading volume of 2,260,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.1% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several brokerages have issued reports on EVAX. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of Evaxion Biotech A/S in a report on Thursday, February 20th. Lake Street Capital lowered their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th.

Evaxion Biotech A/S Trading Up 1.1 %

Shares of NASDAQ:EVAX opened at $1.77 on Thursday. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. The firm has a market capitalization of $2.08 million, a P/E ratio of -1.22 and a beta of -0.25. The business’s 50-day moving average is $2.54 and its 200 day moving average is $7.44. Evaxion Biotech A/S has a 1 year low of $1.67 and a 1 year high of $22.05.

Hedge Funds Weigh In On Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Invst LLC grew its stake in Evaxion Biotech A/S (NASDAQ:EVAX) by 16.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,400 shares of the company’s stock after buying an additional 7,200 shares during the period. Invst LLC owned 4.31% of Evaxion Biotech A/S worth $43,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.